{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:47:44Z","timestamp":1792237664088,"version":"4.4.0"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ejpb.2020.11.004","type":"journal-article","created":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T07:45:20Z","timestamp":1605339920000},"page":"198-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"special_numbering":"C","title":["Physical formulation approaches for improving aqueous solubility and bioavailability of ellagic acid: A review"],"prefix":"10.1016","volume":"159","author":[{"given":"Isa\u00efe","family":"Nyamba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lechanteur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasman\u00e9","family":"Semd\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Evrard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2020.11.004_b0005","article-title":"Challenges to improve the biopharmaceutical properties of poorly water-soluble drugs and the application of the solid dispersion technology","volume":"23","author":"Tambosi","year":"2018","journal-title":"Rev. Mater."},{"key":"10.1016\/j.ejpb.2020.11.004_b0010","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.xphs.2017.08.014","article-title":"Hot Melt Extrudates Formulated Using Design Space: One Simple Process for Both Palatability and Dissolution Rate Improvement","volume":"107","author":"Malaquias","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2020.11.004_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105332","article-title":"Impregnation of mesoporous silica with poor aqueous soluble molecule using pressurized carbon dioxide: is the solubility in the supercritical and subcritical phase a critical parameter?","author":"Koch","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2020.11.004_b0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2017.01.014","article-title":"BCS class IV drugs: Highly notorious candidates for formulation development","volume":"248","author":"Ghadi","year":"2017","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2020.11.004_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111724","article-title":"Ellagic acid a multi-target bioactive compound for drug discovery in CNS? A narrative review","volume":"183","author":"Alfei","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejpb.2020.11.004_b0030","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.phrs.2015.04.008","article-title":"Ellagic acid: Pharmacological activities and molecular mechanisms involved in liver protection","volume":"97","author":"Garc\u00eda-Ni\u00f1o","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejpb.2020.11.004_b0035","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.mam.2010.09.005","article-title":"Ellagitannins, ellagic acid and vascular health","volume":"31","author":"Larrosa","year":"2010","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.ejpb.2020.11.004_b0040","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/pca.1288","article-title":"The quantification of ellagic acid in the crude extract of Phyllanthus amarus Schum. & Thonn. (Euphorbiaceae)","volume":"22","author":"Dhooghe","year":"2011","journal-title":"Phytochem. Anal."},{"key":"10.1016\/j.ejpb.2020.11.004_b0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11010-018-3310-3","article-title":"Ellagic acid in suppressing in vivo and in vitro oxidative stresses","volume":"448","author":"Zeb","year":"2018","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ejpb.2020.11.004_b0050","doi-asserted-by":"crossref","first-page":"289","DOI":"10.17306\/J.AFS.2014.3.7","article-title":"Ellagitannins : a General Review *, Acta Sci","volume":"13","author":"Polonorum","year":"2014","journal-title":"Pol., Technol. Aliment."},{"key":"10.1016\/j.ejpb.2020.11.004_b0055","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1021\/jf802418j","article-title":"Coffee and green tea as a large source of antioxidant polyphenols in the Japanese population","volume":"57","author":"Fukushima","year":"2009","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ejpb.2020.11.004_b0060","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.2174\/1381612822666160125114503","article-title":"Insights Into Effects of Ellagic Acid on the Nervous System: A Mini Review","volume":"22","author":"Ahmed","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejpb.2020.11.004_b0065","first-page":"961","author":"Kang","year":"2016","journal-title":"Improvements in Metabolic Health with Consumption of Ellagic Acid and Subsequent Conversion into Urolithins : Evidence and"},{"key":"10.1016\/j.ejpb.2020.11.004_b0070","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.foodres.2011.04.027","article-title":"Ellagitannins, ellagic acid and their derived metabolites: A review about source, metabolism, functions and health","volume":"44","author":"Landete","year":"2011","journal-title":"Food Res. Int."},{"key":"10.1016\/j.ejpb.2020.11.004_b0075","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3945\/an.116.012575","article-title":"Improvements in Metabolic Health with Consumption of Ellagic Acid and Subsequent Conversion into Urolithins: Evidence and Mechanisms","volume":"7","author":"Kang","year":"2016","journal-title":"Adv. Nutr."},{"key":"10.1016\/j.ejpb.2020.11.004_b0080","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1055\/a-0633-9492","article-title":"A Pharmacological Update of Ellagic Acid","volume":"84","author":"R\u00edos","year":"2018","journal-title":"Planta Med."},{"key":"10.1016\/j.ejpb.2020.11.004_b0085","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1128\/AAC.01175-08","article-title":"In vitro and in vivo properties of ellagic acid in malaria treatment","volume":"53","author":"Soh","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2020.11.004_b0090","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/01616412.2019.1576319","article-title":"Neuroprotective effects of Ellagic acid against acrylamide-induced neurotoxicity in rats","volume":"41","author":"Goudarzi","year":"2019","journal-title":"Neurol. Res."},{"key":"10.1016\/j.ejpb.2020.11.004_b0095","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.tiv.2015.04.008","article-title":"In vitro antiproliferative and antioxidant effects of urolithin A, the colonic metabolite of ellagic acid, on hepatocellular carcinomas HepG2 cells","volume":"29","author":"Wang","year":"2015","journal-title":"Toxicol. Vitr."},{"key":"10.1016\/j.ejpb.2020.11.004_b0100","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/453892","article-title":"Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis","volume":"2010","author":"Kaneto","year":"2010","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.ejpb.2020.11.004_b0105","unstructured":"X. Yang, F.A. Toma, Tea Is a Signi fi cant Dietary Source of Ellagitannins and Ellagic Acid \u0301, (2019). 10.1021\/acs.jafc.8b05010."},{"key":"10.1016\/j.ejpb.2020.11.004_b0110","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1039\/C8NJ05657A","article-title":"Preparation of ellagic acid micro and nano formulations with amazingly increased water solubility by its entrapment in pectin or non-PAMAM dendrimers suitable for clinical applications","volume":"43","author":"Alfei","year":"2019","journal-title":"New J. Chem."},{"key":"10.1016\/j.ejpb.2020.11.004_b0115","doi-asserted-by":"crossref","unstructured":"J. Fotie, ChemInform Abstract: The Potential of Ellagic Acid as a Possible Antimalarial Drug Candidate, ChemInform. 42 (2011) no-no. 10.1002\/chin.201105244.","DOI":"10.1002\/chin.201105244"},{"key":"10.1016\/j.ejpb.2020.11.004_b0120","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.saa.2014.04.052","article-title":"Spectroscopic studies on the antioxidant activity of ellagic acid, Spectrochim. Acta - Part A Mol","volume":"130","author":"Kilic","year":"2014","journal-title":"Biomol. Spectrosc."},{"key":"10.1016\/j.ejpb.2020.11.004_b0125","first-page":"24","article-title":"Seasonal Variation in the Bacterial Content of Oysters","volume":"2","author":"Salminen","year":"2004","journal-title":"Am. J. Public Health."},{"key":"10.1016\/j.ejpb.2020.11.004_b0130","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/476290","article-title":"Erratum to \u201cA comparative study for the evaluation of two doses of ellagic acid on hepatic drug metabolizing and antioxidant enzymes in the rat\u201d","volume":"2014","author":"Celik","year":"2014","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.ejpb.2020.11.004_b0135","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.fct.2012.02.020","article-title":"Ellagic acid protects human keratinocyte (HaCaT) cells against UVA-induced oxidative stress and apoptosis through the upregulation of the HO-1 and Nrf-2 antioxidant genes","volume":"50","author":"Hseu","year":"2012","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.ejpb.2020.11.004_b0140","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2147\/IJN.S21567","article-title":"Development of antiproliferative nanohybrid compound with controlled release property using ellagic acid as the active agent","volume":"6","author":"Hussein","year":"2011","journal-title":"Int. J. Nanomedicine."},{"key":"10.1016\/j.ejpb.2020.11.004_b0145","doi-asserted-by":"crossref","unstructured":"D.V. Ratnam, D.D. Ankola, V. Bhardwaj, D.K. Sahana, M.N.V.R. Kumar, Role of antioxidants in prophylaxis and therapy\u00a0: A pharmaceutical perspective, 113 (2006) 189\u2013207. 10.1016\/j.jconrel.2006.04.015.","DOI":"10.1016\/j.jconrel.2006.04.015"},{"key":"10.1016\/j.ejpb.2020.11.004_b0150","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jpba.2005.07.006","article-title":"Analytical methods for assay of ellagic acid and its solubility studies","volume":"40","author":"Bala","year":"2006","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2020.11.004_b0155","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jconrel.2017.07.047","article-title":"Mesoporous silica materials: From physico-chemical properties to enhanced dissolution of poorly water-soluble drugs","volume":"262","author":"Maleki","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2020.11.004_b0160","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.carbpol.2012.10.051","article-title":"Stability and solubility enhancement of ellagic acid in cellulose ester solid dispersions","volume":"92","author":"Li","year":"2013","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2020.11.004_b0165","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1021\/tx500065y","article-title":"Ellagic acid: An unusually versatile protector against oxidative stress","volume":"27","author":"Galano","year":"2014","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejpb.2020.11.004_b0170","doi-asserted-by":"crossref","unstructured":"J.C. Thermodynamics, J.Z. D\u00e1valos, C.F.R.A.C. Lima, L.M.N.B.F. Santos, V.L. Romero, J.F. Liebman, Thermochemical and structural studies of gallic and ellagic acids, 129 (2019) 108\u2013113. 10.1016\/j.jct.2018.09.027.","DOI":"10.1016\/j.jct.2018.09.027"},{"key":"10.1016\/j.ejpb.2020.11.004_b0175","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jff.2015.09.019","article-title":"Identifying the limits for ellagic acid bioavailability: A crossover pharmacokinetic study in healthy volunteers after consumption of pomegranate extracts","volume":"19","author":"Gonz\u00e1lez-Sarr\u00edas","year":"2015","journal-title":"J. Funct. Foods."},{"key":"10.1016\/j.ejpb.2020.11.004_b0180","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/10611860600565987","article-title":"Sustained release nanoparticulate formulation containing antioxidant-ellagic acid as potential prophylaxis system for oral administration","volume":"14","author":"Bala","year":"2006","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejpb.2020.11.004_b0185","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/nprot.2007.303","article-title":"Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers","volume":"2","author":"Hubatsch","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejpb.2020.11.004_b0190","doi-asserted-by":"crossref","first-page":"289","DOI":"10.17306\/J.AFS.2014.3.7","article-title":"Structure, occurrence and biological activity of ellagitannins: A general review","volume":"13","author":"Lipi\u0144ska","year":"2014","journal-title":"Acta Sci. Pol. Technol. Aliment."},{"key":"10.1016\/j.ejpb.2020.11.004_b0195","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/270418","article-title":"Biological significance of urolithins, the gut microbial ellagic acid-derived metabolites: The evidence so far","volume":"2013","author":"Esp\u00edn","year":"2013","journal-title":"Evidence-Based Complement. Altern. Med."},{"key":"10.1016\/j.ejpb.2020.11.004_b0200","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/mnfr.201100677","article-title":"Ellagitannin metabolites, urolithin A glucuronide and its aglycone urolithin A, ameliorate TNF-\u03b1-induced inflammation and associated molecular markers in human aortic endothelial cells","volume":"56","author":"Gim\u00e9nez-Bastida","year":"2012","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.ejpb.2020.11.004_b0205","doi-asserted-by":"crossref","first-page":"18923","DOI":"10.3390\/molecules191118923","article-title":"Method development and validation for pharmacokinetic and tissue distributions of ellagic acid using ultrahigh performance liquid chromatography-tandem mass spectrometry (UPLC-MS\/MS)","volume":"19","author":"Yan","year":"2014","journal-title":"Molecules."},{"key":"10.1016\/j.ejpb.2020.11.004_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119200","article-title":"Three-dimensional printing technology as a promising tool in bioavailability enhancement of poorly water-soluble molecules: A review","volume":"580","author":"Jennotte","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.11.004_b0215","unstructured":"Biopharm Class. sytem.pdf, (n.d.). 10.1023\/A:1016212804288."},{"key":"10.1016\/j.ejpb.2020.11.004_b0220","article-title":"Journal of Drug Delivery Science and Technology Nanotechnology based approaches to enhance aqueous solubility and bioavailability of griseofulvin : A literature survey","volume":"53","author":"Kumar","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2020.11.004_b0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2011.08.032","article-title":"Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications","volume":"420","author":"Kawabata","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.11.004_b0230","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4172\/jbb.1000027","article-title":"Pharmaceutical Technologies for Enhancing Oral Bioavailability of Poorly Soluble Drugs","volume":"02","author":"Krishnaiah","year":"2010","journal-title":"J. Bioequiv. Availab."},{"key":"10.1016\/j.ejpb.2020.11.004_b0235","doi-asserted-by":"crossref","unstructured":"S. Marques, B. Sarmento, Amorphous solid dispersions\u00a0: Rational selection of a manufacturing process \u2606, 100 (2016) 85\u2013101. 10.1016\/j.addr.2016.01.012.","DOI":"10.1016\/j.addr.2016.01.012"},{"key":"10.1016\/j.ejpb.2020.11.004_b0240","doi-asserted-by":"crossref","unstructured":"H. Jain, N. Chella, Solubility Enhancement Techniques for Natural Product Delivery, 2020. 10.1007\/978-3-030-41838-0.","DOI":"10.1007\/978-3-030-41838-0_2"},{"key":"10.1016\/j.ejpb.2020.11.004_b0245","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.powtec.2015.05.012","article-title":"Amorphous formulations for dissolution and bioavailability enhancement of poorly soluble APIs","volume":"285","author":"Kanaujia","year":"2015","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2020.11.004_b0250","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jddst.2019.01.017","volume":"50","author":"Ma","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol. Characterizat. Amorphous Solid Dispersions Update"},{"key":"10.1016\/j.ejpb.2020.11.004_b0255","unstructured":"K. Nagapudi, J. Jona, Amorphous Active Pharmaceutical Ingredients in Preclinical Studies\u00a0: Amorphous Active Pharmaceutical Ingredients in Preclinical Studies\u00a0: Preparation , Characterization , and Formulation, (2014). 10.2174\/157340708786847852."},{"key":"10.1016\/j.ejpb.2020.11.004_b0260","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1002\/jps.24541","article-title":"Amorphous Solid Dispersions: Utilization and Challenges in Drug Discovery and Development","volume":"104","author":"He","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2020.11.004_b0265","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1021\/mp300386v","article-title":"Construction of drug-polymer thermodynamic phase diagrams using flory-huggins interaction theory: Identifying the relevance of temperature and drug weight fraction to phase separation within solid dispersions","volume":"10","author":"Tian","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2020.11.004_b0270","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/jps.24690","article-title":"Supersaturation and Precipitation of Posaconazole Upon Entry in the Upper Small Intestine in Humans","volume":"105","author":"Hens","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2020.11.004_b0275","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijpharm.2016.10.003","article-title":"Continuous production of itraconazole-based solid dispersions by hot melt extrusion: Preformulation, optimization and design space determination","volume":"515","author":"Thiry","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.11.004_b0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics12040357","article-title":"Improved dissolution and pharmacokinetics of abiraterone through kinetisol\u00ae enabled amorphous solid dispersions","volume":"12","author":"Gala","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2020.11.004_b0285","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1016\/j.xphs.2015.10.008","article-title":"Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs","volume":"105","author":"Baghel","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2020.11.004_b0290","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ijpharm.2012.07.015","article-title":"Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: Formulation and process considerations","volume":"453","author":"Paudel","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.11.004_b0295","doi-asserted-by":"crossref","unstructured":"Y. Liu, C. Sun, Y. Hao, T. Jiang, L. Zheng, S. Wang, Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles, J. Pharm. Pharm. Sci. 13 (2010) 589\u2013606. 10.18433\/j3530j.","DOI":"10.18433\/J3530J"},{"key":"10.1016\/j.ejpb.2020.11.004_b0300","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/jps.23146","article-title":"Molecular Nanomedicine Towards Cancer","volume":"101","author":"Psimadas","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2020.11.004_b0305","article-title":"An approach for chemical stability during melt extrusion of a drug substance with a high melting point","author":"Haser","year":"2017","journal-title":"Elsevier B.V."},{"key":"10.1016\/j.ejpb.2020.11.004_b0310","unstructured":"S.S. Jambhekar, P. Breen, Cyclodextrins in pharmaceutical formulations I\u00a0: structure and physicochemical properties , formation of complexes , and types of complex O OH OH OH OH OH HO HO HO O HO OH HO HO HO, 21 (2016)."},{"key":"10.1016\/j.ejpb.2020.11.004_b0315","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0032-9592(03)00258-9","article-title":"Cyclodextrins and their uses: A review","volume":"39","author":"Del Valle","year":"2004","journal-title":"Process Biochem."},{"key":"10.1016\/j.ejpb.2020.11.004_b0320","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1021\/cr970022c","article-title":"Introduction and general overview of cyclodextrin chemistry","volume":"98","author":"Szejtli","year":"1998","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejpb.2020.11.004_b0325","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ddr.21452","article-title":"Cyclodextrin complexes: Perspective from drug delivery and formulation","volume":"79","author":"Jacob","year":"2018","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejpb.2020.11.004_b0330","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.molstruc.2017.03.116","article-title":"Inclusion complex of nateglinide with sulfobutyl ether \u03b2-cyclodextrin: Preparation, characterization and water solubility","volume":"1141","author":"Xu","year":"2017","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejpb.2020.11.004_b0335","first-page":"1030","article-title":"Applications of cyclodextrins : formation of inclusion complexes and their characterization Radhouan MAAZAOUI and Raoudha ABDERRAHIM * Laboratory of Physics of Lamellaires Materials and Hybrids Nanomaterials, University of Carthage, Faculty of Sciences","volume":"3","author":"Maazaoui","year":"2015","journal-title":"Int. J. Adv. Res."},{"key":"10.1016\/j.ejpb.2020.11.004_b0340","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.addr.2007.05.012","article-title":"Cyclodextrins as pharmaceutical solubilizers","volume":"59","author":"Brewster","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2020.11.004_b0345","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijpharm.2017.11.018","article-title":"Cyclodextrins: structure, physicochemical properties and pharmaceutical applications","volume":"535","author":"Jansook","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.11.004_b0350","doi-asserted-by":"crossref","unstructured":"E. Pinho, M. Grootveld, M. Henriques, Cyclodextrins as encapsulation agents for plant bioactive compounds, 101 (2014) 121\u2013135. 10.1016\/j.carbpol.2013.08.078.","DOI":"10.1016\/j.carbpol.2013.08.078"},{"key":"10.1016\/j.ejpb.2020.11.004_b0355","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ejpb.2013.06.011","article-title":"Targeted gene delivery by new folate-polycationic amphiphilic cyclodextrin-DNA nanocomplexes in vitro and in vivo","volume":"85","author":"Aranda","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2020.11.004_b0360","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ijpharm.2017.04.050","article-title":"Cyclodextrin nanosystems in oral drug delivery: A mini review","volume":"531","author":"Adeoye","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.11.004_b0365","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/pharmaceutics12010055","article-title":"Influence of Composition and Spray-Drying Process Parameters on Carrier-Free DPI Properties and Behaviors in the Lung: A review","volume":"12","author":"Lechanteur","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2020.11.004_b0370","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1002\/jps.23077","article-title":"Cyclodextrins as functional excipients: Methods to enhance complexation efficiency","volume":"101","author":"Loftsson","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2020.11.004_b0375","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ejpb.2014.08.012","article-title":"Self-assembled biotransesterified cyclodextrins as potential Artemisinin nanocarriers. II: In vitro behavior toward the immune system and in vivo biodistribution assessment of unloaded nanoparticles","volume":"88","author":"Yam\u00e9ogo","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2020.11.004_b0380","doi-asserted-by":"crossref","first-page":"10940","DOI":"10.1021\/cr500081p","article-title":"Review: A history of cyclodextrins","volume":"114","author":"Crini","year":"2014","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejpb.2020.11.004_b0385","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/10837450.2018.1502318","article-title":"The effect of complexation with cyclodextrins on the antioxidant and antimicrobial activity of ellagic acid","volume":"24","author":"Savic","year":"2019","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2020.11.004_b0390","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10847-015-0498-7","article-title":"Characterisation and anti-inflammatory evaluation of the inclusion complex of ellagic acid with hydroxypropyl-\u03b2-cyclodextrin","volume":"82","author":"Bulani","year":"2015","journal-title":"J. Incl. Phenom. Macrocycl. Chem."},{"key":"10.1016\/j.ejpb.2020.11.004_b0395","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.molstruc.2015.08.054","article-title":"Inclusion complex of ellagic acid with \u03b2-cyclodextrin: Characterization and in vitro anti-inflammatory evaluation","volume":"1105","author":"Bulani","year":"2016","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejpb.2020.11.004_b0400","doi-asserted-by":"crossref","unstructured":"Y.N. Chudasama, A. Lugea, Q.Y. Lu, S.J. Pandol, S-860, Gastroenterology. 140 (2005) S-860. 10.1016\/S0016-5085(11)63573-7.","DOI":"10.1016\/S0016-5085(11)63573-7"},{"key":"10.1016\/j.ejpb.2020.11.004_b0405","unstructured":"F.M. Mady, S. Ragab, M. Ibrahim, Cyclodextrin-based nanosponge for improvement of solubility and oral bioavailability of Ellagic acid, 31 (2018) 2069\u20132076."},{"key":"10.1016\/j.ejpb.2020.11.004_b0410","first-page":"304","article-title":"Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability","volume":"9","author":"Khadka","year":"2014","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2020.11.004_b0415","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ddtec.2018.04.004","article-title":"Physicochemical characterisation in drug discovery Automated assays for thermodynamic (equilibrium) solubility determination","volume":"27","author":"Sou","year":"2018","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejpb.2020.11.004_b0420","first-page":"1","article-title":"Drug Solubility: Importance and Enhancement Techniques","volume":"2012","author":"Savjani","year":"2012","journal-title":"ISRN Pharm."},{"key":"10.1016\/j.ejpb.2020.11.004_b0425","doi-asserted-by":"crossref","unstructured":"R. Shegokar, R.H. M\u00fcller, Nanocrystals\u00a0: Industrially feasible multifunctional formulation technology for poorly soluble actives, 399 (2010) 129\u2013139. 10.1016\/j.ijpharm.2010.07.044.","DOI":"10.1016\/j.ijpharm.2010.07.044"},{"key":"10.1016\/j.ejpb.2020.11.004_b0430","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/pr.112.005660","article-title":"Strategies to address low drug solubility in discovery and development","volume":"65","author":"Williams","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejpb.2020.11.004_b0435","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ijpharm.2015.03.071","article-title":"Preparation and characterization of micronized ellagic acid using antisolvent precipitation for oral delivery","volume":"486","author":"Li","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.11.004_b0440","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.supflu.2016.05.019","article-title":"Generation of microparticles of ellagic acid by supercritical antisolvent process","volume":"116","author":"Montes","year":"2016","journal-title":"J. Supercrit. Fluids."},{"key":"10.1016\/j.ejpb.2020.11.004_b0445","doi-asserted-by":"crossref","unstructured":"Y.-I. Jeong, R.P. Yv, T. Ohno, Y. Yoshikawa, N. Shibata, S. Kato, K. Takeuchi, K. Takada, Application of Eudragit P-4135F for the delivery of ellagic acid to the rat lower small intestine, J. Pharm. Pharmacol. 53 (2001) 1079\u20131085. 10.1211\/0022357011776469.","DOI":"10.1211\/0022357011776469"},{"key":"10.1016\/j.ejpb.2020.11.004_b0450","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1039\/C8NJ05657A","article-title":"Preparation of ellagic acid micro and nano formulations with amazingly increased water solubility by its entrapment in pectin or non-PAMAM dendrimers suitable for clinical applications","volume":"43","author":"Alfei","year":"2019","journal-title":"New J. Chem."},{"key":"10.1016\/j.ejpb.2020.11.004_b0455","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1088\/0957-4484\/16\/12\/014","article-title":"Design of biodegradable nanoparticles: A novel approach to encapsulating poorly soluble phytochemical ellagic acid","volume":"16","author":"Bala","year":"2005","journal-title":"Nanotechnology"},{"key":"10.1016\/j.ejpb.2020.11.004_b0460","doi-asserted-by":"crossref","first-page":"7405","DOI":"10.2147\/IJN.S147740","article-title":"Enhanced anticancer activity and oral bioavailability of ellagic acid through encapsulation in biodegradable polymeric nanoparticles","volume":"12","author":"Mady","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2020.11.004_b0465","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jddst.2018.05.021","article-title":"Novel oral administrated ellagic acid nanoparticles for enhancing oral bioavailability and anti-inflammatory efficacy","volume":"46","author":"Ruan","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2020.11.004_b0470","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.addr.2011.02.001","article-title":"Physical and chemical stability of drug nanoparticles","volume":"63","author":"Wu","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2020.11.004_b0475","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s11095-015-1843-7","article-title":"A new in vitro lipid digestion - In vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations","volume":"33","author":"Crum","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2020.11.004_b0480","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0928-0987(00)00167-6","article-title":"Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying and \u201cself-microemulsifying\u201d drug delivery systems","volume":"11","author":"Pouton","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2020.11.004_b0485","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ejps.2006.04.016","article-title":"Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system","volume":"29","author":"Pouton","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2020.11.004_b0490","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.apsb.2013.10.001","article-title":"Oral lipid-based drug delivery systems \u2013 an overview","volume":"3","author":"Kalepu","year":"2013","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.ejpb.2020.11.004_b0495","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ijpharm.2013.03.054","article-title":"Lipid-based formulations for oral administration of poorly water-soluble drugs","volume":"453","author":"Mu","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.11.004_b0500","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.addr.2007.10.010","article-title":"Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies","volume":"60","author":"Pouton","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2020.11.004_b0505","doi-asserted-by":"crossref","unstructured":"C. Gu, H. Li, J. Levons, K. Lentz, R.B. Gandhi, K. Raghavan, R.L. Smith, Predicting Effect of Food on Extent of Drug Absorption Based on Physicochemical Properties, 24 (2007) 1118\u20131130. 10.1007\/s11095-007-9236-1.","DOI":"10.1007\/s11095-007-9236-1"},{"key":"10.1016\/j.ejpb.2020.11.004_b0510","doi-asserted-by":"crossref","unstructured":"A. M\u00fcllertz, A. Ogbonna, S. Ren, New perspectives on lipid and surfactant based drug, (2010) 1622\u20131636. 10.1111\/j.2042-7158.2010.01107.x.","DOI":"10.1111\/j.2042-7158.2010.01107.x"},{"key":"10.1016\/j.ejpb.2020.11.004_b0515","doi-asserted-by":"crossref","first-page":"7945","DOI":"10.1021\/jm3006433","article-title":"Application of lipid-based formulations in drug discovery","volume":"55","author":"Chen","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2020.11.004_b0520","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1080\/03639045.2017.1342654","article-title":"Review and analysis of FDA approved drugs using lipid-based formulations","volume":"43","author":"Savla","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2020.11.004_b0525","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jff.2017.04.033","article-title":"A food-grade self-nanoemulsifying delivery system for enhancing oral bioavailability of ellagic acid","volume":"34","author":"Wang","year":"2017","journal-title":"J. Funct. Foods."},{"key":"10.1016\/j.ejpb.2020.11.004_b0530","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jsps.2014.11.001","article-title":"Self nanoemulsifying drug delivery system of stabilized ellagic acid-phospholipid complex with improved dissolution and permeability","volume":"23","author":"Avachat","year":"2015","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.ejpb.2020.11.004_b0535","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1021\/jf8037105","article-title":"Enhanced oral bioavailability and antioxidant profile of ellagic acid by phospholipids","volume":"57","author":"Murugan","year":"2009","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ejpb.2020.11.004_b0540","article-title":"Preparation of a supersaturatable self-microemulsion as drug delivery system for ellagic acid and evaluation of its antioxidant activities","volume":"53","author":"Zheng","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2020.11.004_b0545","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3109\/10717544.2014.898714","article-title":"Rational formulation strategy from drug discovery profiling to human proof of concept","volume":"22","author":"Ayad","year":"2015","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2020.11.004_b0550","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3109\/10837450.2014.882938","article-title":"Amorphous solid dispersion with increased gastric solubility in tandem with oral disintegrating tablets: A successful approach to improve the bioavailability of atorvastatin","volume":"20","author":"Salmani","year":"2015","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2020.11.004_b0555","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ejpb.2015.06.002","article-title":"Curcumin-Eudragit\u00ae e PO solid dispersion: A simple and potent method to solve the problems of curcumin","volume":"94","author":"Li","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2020.11.004_b0560","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ijpharm.2011.08.007","article-title":"Thermal processing of a poorly water-soluble drug substance exhibiting a high melting point: The utility of KinetiSol \u00ae Dispersing","volume":"419","author":"Hughey","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.11.004_b0565","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1208\/s12249-018-1007-2","article-title":"Expanding the Application and Formulation Space of Amorphous Solid Dispersions with KinetiSol\u00ae: a Review","volume":"19","author":"Ellenberger","year":"2018","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.ejpb.2020.11.004_b0570","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejps.2013.03.018","article-title":"Reduction of melting temperature and enthalpy of drug crystals: Theoretical aspects","volume":"50","author":"Hasa","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2020.11.004_b0575","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijpharm.2005.01.020","article-title":"Preparation and characterization of poly-\u03b5-caprolactone nanoparticles containing griseofulvin","volume":"294","author":"Zili","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.11.004_b0580","article-title":"Nanotechnology based approaches to enhance aqueous solubility and bioavailability of griseofulvin: A literature survey","volume":"53","author":"Kumar","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2020.11.004_b0585","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ijpharm.2014.12.036","article-title":"A review of pharmaceutical extrusion: Critical process parameters and scaling-up","volume":"479","author":"Thiry","year":"2015","journal-title":"Int. J. Pharm."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964112030326X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964112030326X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:43:55Z","timestamp":1760546635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S093964112030326X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":117,"alternative-id":["S093964112030326X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2020.11.004","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physical formulation approaches for improving aqueous solubility and bioavailability of ellagic acid: A review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2020.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}